Table 5.

Limiting dilution study of week 4–expanded CB cells

Cell dosePrimary miceSecondary mice
% CD45+% CD45+/GFP+% CD45+% CD45+/GFP+ME5-150
30 000 9.21 15.41 8.3 16.7 
 9.26 21.47 9.4 10.2 
 12.4 16.9 ND ND ND 
 7.4 18.5 6.4 17.9 +  
20 000      
 5.4 17.2 3.6 11.2 
 6.2 9.2 1.3 13.6 
 4.5 18.9 2.5 7.8 
 3.6 11.7 ND ND ND  
10 000      
 2.3 12 ND ND ND 
 1.7 14.3 ND ND ND 
 4.2 25.7 ND ND ND 
 1.0 58 ND ND ND 
Cell dosePrimary miceSecondary mice
% CD45+% CD45+/GFP+% CD45+% CD45+/GFP+ME5-150
30 000 9.21 15.41 8.3 16.7 
 9.26 21.47 9.4 10.2 
 12.4 16.9 ND ND ND 
 7.4 18.5 6.4 17.9 +  
20 000      
 5.4 17.2 3.6 11.2 
 6.2 9.2 1.3 13.6 
 4.5 18.9 2.5 7.8 
 3.6 11.7 ND ND ND  
10 000      
 2.3 12 ND ND ND 
 1.7 14.3 ND ND ND 
 4.2 25.7 ND ND ND 
 1.0 58 ND ND ND 

Cell-dose limiting dilution of transduced CB CD34+cells (TU 50 × 106/mL or MOI 50). Cells at the indicated doses were preincubated for 4 days with FL, TPO, SCF, and IL6; incubated overnight with viral particles; and subsequently grown with the same growth factors for a total of 4 weeks. All progeny cells were harvested and inoculated into sublethally irradiated NOD/SCID mice. The mice were killed 6 to 8 weeks after transplantation and the harvested BM was assessed for levels of human engraftment and percentage of GFP-expressing cells. Five to 15 million unfractionated BM cells from each primary mouse were inoculated into a single secondary sublethally irradiated NOD/SCID mouse, which was killed 6 to 8 weeks later.

F5-150

Multilineage engraftment (ME) was defined by the presence of CD19+, CD34+, CD14+, CD33+, and CD41+ cells within the CD45 gate and by anti–glycophorin-A+ cells in the total BM.

ND indicates not done.

Close Modal

or Create an Account

Close Modal
Close Modal